1610758-18-3

Upstream product

• 211915-84-3 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid ethyl ester 
• 212322-77-5 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propionic acid 
• 104-15-4 toluene-4-sulfonic acid 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 1610758-19-4 C₃₅H₄₃N₇O₅ 

Relevant academic research and scientific papers

Identification, synthesis, and strategy for the reduction of potential impurities observed in dabigatran etexilate mesylate processes

Synthetic impurities that are present in dabigatran etexilate mesylate were studied, and possible pathways by which these impurities are formed during the manufacturing process were examined. The impurities were monitored by high-performance liquid chromatography, and their structures were determined by mass spectrometry and 1H and 13C NMR. Potential causes for the formation of these impurities are discussed, and strategies to minimize their formation are also described.